Department of Health and Human Services U.S. Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Silver Spring, MD 20993

September 17, 2008

Licensing Assistant Section Nuclear Materials Safety Branch U.S. Nuclear Regulatory Commission, Region I 475 Allendale Road King of Prussia, PA 19406-1415

Br.2

Dear Madam/Sir:

Due to a serious illness, Dr. John Strong, who as the Acting Director of the Laboratory of Clinical Pharmacology (LCP) is listed as the licensee on Materials License # 19-07538-05, has decided to retire from the government effective 9/30/08.

In addition to serving as the Radiation Safety Officer (RSO) on Materials License # 19-07538-05, I have being appointed as Acting Director for LCP following Dr. Strong's departure from FDA.

It is the intention of FDA management to replace Dr. Strong with a permanent LCP Director within the next 12 months. As head of the Laboratory, the new Director would assume Dr. Strong's position as the listed licensee on Materials License # 19-07538-05.

Thanks for your assistance.

Sincerely,

Robert Parker Ph.D., Acting Director Laboratory of Clinical Pharmacology

Office of Testing and Research

Center for Drug Evaluation and Research

U.S. Food and Drug Administration, DHHS

Life Sciences Building 64 / Rm 2018

10903 New Hampshire Ave

Silver Spring, MD 20993

Phone (301) 796-0117

Fax (301) 796-9818

Email robertj.parker@fda.hhs.gov

142818 nmss/rgni mater.als-002

There were no administrative review has technical reviewer. Please note omissions or require additional in	issions. Your application was assigned to a that the technical review may identify additional
A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved. Your action has been assigned Mail Control Number	